Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2023

18-04-2023 | Hepatitis B | Original Article

Prognostic Effects of Liver Fibrosis and Steatosis Determined Using Transient Elastography in Patients with Chronic Hepatitis B or C

Authors: Chun-Li Wang, Chien-Hao Huang, Victor Chien-Chia Wu, Chia-Ling Wu, Yu-Tung Huang, Shang-Hung Chang

Published in: Digestive Diseases and Sciences | Issue 6/2023

Login to get access

Abstract

Background

The prognostic effects of liver fibrosis and steatosis in patients with chronic hepatitis B or C are unclear. We investigated the prognostic effects of liver fibrosis and steatosis determined through transient elastography (TE) in patients with chronic hepatitis B or C.

Methods

This retrospective cohort study enrolled 5528 patients with chronic hepatitis B or C who received TE. Multivariate Cox regression was used to evaluate the associations between fibrosis and steatosis grades and the occurrence of hepatic-related events, cardiovascular events, and mortality. Liver stiffness measurements of ≥ 7.1, ≥ 9.5, and ≥ 12.5 kPa were considered to indicate significant fibrosis (≥ F2), advanced fibrosis (≥ F3), and cirrhosis (≥ F4), and controlled attenuation parameters of ≥ 230 and ≥ 264 dB/m were considered to indicate mild (S1) and moderate-to-severe (S2–S3) steatosis, respectively.

Results

During a median follow-up of 3.1 years, 489 patients died, 814 had hepatic-related events, and 209 had cardiovascular events. The incidences of these outcomes were lowest among individuals with no- or mild-fibrosis (F0–F1), and increased with fibrosis severity. The incidence of adverse outcomes was highest among patients without steatosis (S0) and lowest among those with moderate-to-severe steatosis. Adjusted models indicated that F2, F3, and F4 were independent risk factors and that moderate-to-severe steatosis was a favorable marker for hepatic-related events. Cirrhosis was an independent factor for mortality.

Conclusions

According to TE, increasing fibrosis grades and absence of steatosis were associated with higher risks of hepatic-related events, whereas cirrhosis was a risk factor for mortality in patients with chronic hepatitis B or C.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kavak S, Kaya S, Senol A, Sogutcu N. Evaluation of liver fibrosis in chronic hepatitis B patients with 2D shear wave elastography with propagation map guidance: a single-centre study. BMC Med Imaging. 2022;22:50.CrossRefPubMedPubMedCentral Kavak S, Kaya S, Senol A, Sogutcu N. Evaluation of liver fibrosis in chronic hepatitis B patients with 2D shear wave elastography with propagation map guidance: a single-centre study. BMC Med Imaging. 2022;22:50.CrossRefPubMedPubMedCentral
2.
go back to reference Zeng DW, Dong J, Liu YR, Jiang JJ, Zhu YY. Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection. World J Gastroenterol. 2016;22:6663–6672.CrossRefPubMedPubMedCentral Zeng DW, Dong J, Liu YR, Jiang JJ, Zhu YY. Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection. World J Gastroenterol. 2016;22:6663–6672.CrossRefPubMedPubMedCentral
4.
go back to reference Carmona I, Cordero P, Ampuero J, Rojas A, Romero-Gómez M. Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. Clin Microbiol Infect. 2016;22:839–845.CrossRefPubMed Carmona I, Cordero P, Ampuero J, Rojas A, Romero-Gómez M. Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. Clin Microbiol Infect. 2016;22:839–845.CrossRefPubMed
5.
go back to reference Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007;47:598–607.CrossRefPubMed Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007;47:598–607.CrossRefPubMed
6.
go back to reference Shiha G, Ibrahim A, Helmy A et al. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatol Int. 2017;11:1–30.CrossRefPubMed Shiha G, Ibrahim A, Helmy A et al. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatol Int. 2017;11:1–30.CrossRefPubMed
7.
go back to reference Bota S, Herkner H, Sporea I et al. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. Liver Int. 2013;33:1138–1147.CrossRefPubMed Bota S, Herkner H, Sporea I et al. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. Liver Int. 2013;33:1138–1147.CrossRefPubMed
9.
go back to reference de Lédinghen V, Vergniol J, Capdepont M et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol. 2014;60:1026–1031.CrossRefPubMed de Lédinghen V, Vergniol J, Capdepont M et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol. 2014;60:1026–1031.CrossRefPubMed
10.
go back to reference Kim SU, Lee JH, Kim DY et al. Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS ONE 2012;7:e36676.CrossRefPubMedPubMedCentral Kim SU, Lee JH, Kim DY et al. Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS ONE 2012;7:e36676.CrossRefPubMedPubMedCentral
11.
go back to reference Gomez-Moreno AZ, Pineda-Tenor D, Jimenez-Sousa MA et al. Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: a retrospective study. PLoS ONE 2017;12:e0184404.CrossRefPubMedPubMedCentral Gomez-Moreno AZ, Pineda-Tenor D, Jimenez-Sousa MA et al. Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: a retrospective study. PLoS ONE 2017;12:e0184404.CrossRefPubMedPubMedCentral
12.
go back to reference de Lédinghen V, Vergniol J, Barthe C et al. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus. Aliment Pharmacol Ther. 2013;37:979–988.CrossRefPubMed de Lédinghen V, Vergniol J, Barthe C et al. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus. Aliment Pharmacol Ther. 2013;37:979–988.CrossRefPubMed
13.
go back to reference Vergniol J, Foucher J, Terrebonne E et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology. 2011;140:1970–1979.CrossRefPubMed Vergniol J, Foucher J, Terrebonne E et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology. 2011;140:1970–1979.CrossRefPubMed
14.
go back to reference Hwang SJ, Luo JC, Chu CW et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol. 2001;16:190–195.CrossRefPubMed Hwang SJ, Luo JC, Chu CW et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol. 2001;16:190–195.CrossRefPubMed
15.
go back to reference Lesmana LA, Lesmana CR, Pakasi LS, Krisnuhoni E. Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity. Acta Med Indones. 2012;44:35–39.PubMed Lesmana LA, Lesmana CR, Pakasi LS, Krisnuhoni E. Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity. Acta Med Indones. 2012;44:35–39.PubMed
16.
go back to reference Huang Y, Gan Q, Lai R et al. Application of fatty liver inhibition of progression algorithm and steatosis, activity, and fibrosis score to assess the impact of non-alcoholic fatty liver on untreated chronic hepatitis B patients. Front Cell Infect Microbiol. 2021;11:733348.CrossRefPubMed Huang Y, Gan Q, Lai R et al. Application of fatty liver inhibition of progression algorithm and steatosis, activity, and fibrosis score to assess the impact of non-alcoholic fatty liver on untreated chronic hepatitis B patients. Front Cell Infect Microbiol. 2021;11:733348.CrossRefPubMed
17.
go back to reference Peleg N, Issachar A, Sneh Arbib O et al. Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load. JHEP Rep. 2019;1:9–16.CrossRefPubMedPubMedCentral Peleg N, Issachar A, Sneh Arbib O et al. Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load. JHEP Rep. 2019;1:9–16.CrossRefPubMedPubMedCentral
18.
go back to reference Peleg N, Issachar A, Sneh Arbib O et al. Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response. J Viral Hepat. 2019;26:1257–1265.CrossRefPubMed Peleg N, Issachar A, Sneh Arbib O et al. Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response. J Viral Hepat. 2019;26:1257–1265.CrossRefPubMed
19.
go back to reference Wong SW, Chan WK, Mohamed R. Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B. J Viral Hepat. 2020;27:1297–1305.CrossRefPubMed Wong SW, Chan WK, Mohamed R. Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B. J Viral Hepat. 2020;27:1297–1305.CrossRefPubMed
20.
go back to reference Rau M, Buggisch P, Mauss S et al. Prognostic impact of steatosis in the clinical course of chronic HCV infection-results from the German Hepatitis C-Registry. PLoS ONE. 2022;17:e0264741.CrossRefPubMedPubMedCentral Rau M, Buggisch P, Mauss S et al. Prognostic impact of steatosis in the clinical course of chronic HCV infection-results from the German Hepatitis C-Registry. PLoS ONE. 2022;17:e0264741.CrossRefPubMedPubMedCentral
21.
go back to reference EASL-ALEH Clinical Practice Guidelines. Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237–264.CrossRef EASL-ALEH Clinical Practice Guidelines. Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237–264.CrossRef
22.
go back to reference Liu CH, Liang CC, Huang KW et al. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol. 2011;6:1057–1065.CrossRefPubMedPubMedCentral Liu CH, Liang CC, Huang KW et al. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol. 2011;6:1057–1065.CrossRefPubMedPubMedCentral
23.
go back to reference Castéra L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–350.CrossRefPubMed Castéra L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–350.CrossRefPubMed
24.
go back to reference Petroff D, Blank V, Newsome PN et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:185–198.CrossRefPubMed Petroff D, Blank V, Newsome PN et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:185–198.CrossRefPubMed
25.
go back to reference Fujii H, Iwaki M, Hayashi H, et al. Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study. Clin Gastroenterol Hepatol. 2022. Fujii H, Iwaki M, Hayashi H, et al. Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study. Clin Gastroenterol Hepatol. 2022.
26.
go back to reference Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19:2138-2147.e2110.CrossRefPubMed Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19:2138-2147.e2110.CrossRefPubMed
27.
go back to reference Christiansen KM, Mössner BK, Hansen JF et al. Liver stiffness measurement among patients with chronic hepatitis B and C: results from a 5-year prospective study. PLoS ONE. 2014;9:e111912.CrossRefPubMedPubMedCentral Christiansen KM, Mössner BK, Hansen JF et al. Liver stiffness measurement among patients with chronic hepatitis B and C: results from a 5-year prospective study. PLoS ONE. 2014;9:e111912.CrossRefPubMedPubMedCentral
28.
go back to reference Hui RWH, Seto WK, Cheung KS et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study. J Viral Hepat. 2018;25:97–104.CrossRefPubMed Hui RWH, Seto WK, Cheung KS et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study. J Viral Hepat. 2018;25:97–104.CrossRefPubMed
31.
go back to reference Mak LY, Hui RW, Fung J et al. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. Hepatol Int. 2021;15:901–911.CrossRefPubMed Mak LY, Hui RW, Fung J et al. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. Hepatol Int. 2021;15:901–911.CrossRefPubMed
32.
go back to reference Oh JH, Lee HW, Sinn DH et al. Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. Hepatol Int. 2021;15:892–900.CrossRefPubMed Oh JH, Lee HW, Sinn DH et al. Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. Hepatol Int. 2021;15:892–900.CrossRefPubMed
33.
go back to reference Wong GL, Wong VW, Choi PC et al. On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. Antivir Ther. 2011;16:165–172.CrossRefPubMed Wong GL, Wong VW, Choi PC et al. On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. Antivir Ther. 2011;16:165–172.CrossRefPubMed
34.
go back to reference Piedade J, Pereira G, Guimarães L et al. Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes. Sci Rep. 2021;11:11681.CrossRefPubMedPubMedCentral Piedade J, Pereira G, Guimarães L et al. Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes. Sci Rep. 2021;11:11681.CrossRefPubMedPubMedCentral
35.
go back to reference Chen Yi Mei SLG, Thompson AJ, Christensen B, et al. Sustained virological response halts fibrosis progression: a long-term follow-up study of people with chronic hepatitis C infection. PLoS ONE. 2017;12:e0185609. Chen Yi Mei SLG, Thompson AJ, Christensen B, et al. Sustained virological response halts fibrosis progression: a long-term follow-up study of people with chronic hepatitis C infection. PLoS ONE. 2017;12:e0185609.
36.
go back to reference Wang Y, Fan Q, Wang T et al. Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis. Int J Clin Exp Med. 2015;8:17654–17663.PubMedPubMedCentral Wang Y, Fan Q, Wang T et al. Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis. Int J Clin Exp Med. 2015;8:17654–17663.PubMedPubMedCentral
Metadata
Title
Prognostic Effects of Liver Fibrosis and Steatosis Determined Using Transient Elastography in Patients with Chronic Hepatitis B or C
Authors
Chun-Li Wang
Chien-Hao Huang
Victor Chien-Chia Wu
Chia-Ling Wu
Yu-Tung Huang
Shang-Hung Chang
Publication date
18-04-2023
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2023
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-023-07943-z

Other articles of this Issue 6/2023

Digestive Diseases and Sciences 6/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.